Evaluation of Pain and Inflammation After Injection of Lucentis vs Eylea for Treatment of Wet Macular Degeneration

Completed · Phase 1/Phase 2

Conditions studied: Neovascular Age-Related Macular Degeneration

In brief

This study is designed to compare the post injection inflammation and pain seen after intravitreal injections of Ranibizumab vs Aflibercept.

Key facts

Study ID

NCT01926977

Run by

Arshad Khanani

People needed

100

Starts

2013-09-01

Expected to finish

2014-05-01

Last updated by the study team

2016-03-03

Who can join

Age: 65 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Able to provide informed consent and comply with study assessments for the full duration of the study
• Age >/= 65 years
• New onset Neovascular Age-Related Macular Degeneration or (See No.4)
• Previously treated Neovascular Age-Related Macular Degeneration with Lucentis or Eylea intravitreal injections
• Visual Acuity of 20/400 or better
• No history of Post injection pain or inflammation with prior treatments -

You may not qualify if…

• History of Endophthalmitis in either eye
• Uncontrolled or symptomatic Dry Eye Syndrome
• History of Anterior or Posterior Uveitis
• History of Post injection pain or inflammation with prior treatments
• Recent thromboembolic event(<3 months)
• Pregnancy(positive pregnancy test) or Lactation/Premenopausal women not using adequate contraception -

Where it is running

• Sierra Eye Associates — Reno, Nevada, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.